Recently, a patient with advanced pancreatic cancer who had failed multiple prior treatment lines achieved sustained tumor shrinkage after receiving KD-496 CAR-T cell therapy, with confirmed remission maintained at 180 days post-treatment.
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
The patient, a 73-year-old female, was diagnosed in July 2021 with a pancreatic head mass accompanied by low bile duct obstruction. She underwent a duodenectomy, during which a firm mass approximately 3 cm in size was found at the pancreatic head uncinate process. Pathological examination confirmed moderately differentiated adenocarcinoma. Postoperatively, she received albumin-bound paclitaxel (nab-paclitaxel) combined with S-1 chemotherapy, followed by M108 + nab-paclitaxel + gemcitabine and LM108 combined with toripalimab. She had a history of schizophrenia and diabetes, both well-controlled with medication.
In February 2025, the patient received an infusion of KD-496 CAR-T cells. At the first tumor assessment four weeks later, despite her advanced age and high tumor burden (baseline target lesion of 58 mm), the target lesion had shrunk by 34.5% from baseline. By day 60, the target lesion had further reduced by 37.9%, and by days 90 and 180, the tumor continued to shrink by 44.8%, maintaining a partial response (PR) without significant gastrointestinal or neurological toxicity.
A 70-year-old gastric cancer patient underwent surgery in February 2023, with postoperative pathology revealing an ulcerative moderately to poorly differentiated adenocarcinoma that had already metastasized to lymph nodes, the peritoneum, and both lungs, accompanied by ascites and pleural effusion (advanced, widely metastatic disease). Eight weeks after surgery, she received SOX chemotherapy (oxaliplatin + S-1), but her condition progressed. Subsequent attempts with PX (paclitaxel) + PD-1 (immunotherapy) for four cycles, followed by capecitabine + nivolumab, also failed to halt progression. Finally, nivolumab + fruquintinib (an anti-angiogenic drug) was administered, but with limited efficacy.
On day 28 of CAR-T therapy, the tumor had shrunk by 47.3% compared to pre-treatment, achieving a deep partial response (PR). By day 60, the tumor continued to shrink by 41.9%, maintaining a confirmed PR, indicating sustained and effective treatment.
A 55-year-old gastric cancer patient underwent laparoscopic radical gastrectomy in November 2023, with postoperative pathology showing poorly differentiated adenocarcinoma with partial signet-ring cell carcinoma (highly malignant). She tried multiple chemotherapy + immunotherapy regimens, including oxaliplatin + capecitabine + sintilimab, oxaliplatin + leucovorin + sintilimab, nab-paclitaxel + sintilimab + fruquintinib, and irinotecan monotherapy. However, in February 2025, her condition rapidly progressed, rendering conventional treatments ineffective.
She then received CAR-T cell therapy, and by day 28, the tumor had shrunk by 31.8% compared to pre-treatment, achieving a partial response (PR), with disease control successfully achieved.
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Post time: Jul-31-2025